CHICAGO TRUST Co NA Decreases Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

CHICAGO TRUST Co NA trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 31.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,733 shares of the company's stock after selling 1,257 shares during the period. CHICAGO TRUST Co NA's holdings in IDEXX Laboratories were worth $1,130,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. FSA Wealth Management LLC bought a new position in IDEXX Laboratories in the third quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock valued at $34,000 after buying an additional 60 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at $37,000. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at $36,000. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded up $4.57 during trading hours on Monday, hitting $422.62. The company's stock had a trading volume of 647,140 shares, compared to its average volume of 562,514. The stock has a market cap of $34.61 billion, a PE ratio of 40.75, a price-to-earnings-growth ratio of 3.94 and a beta of 1.36. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The company has a 50 day moving average of $423.76 and a 200 day moving average of $459.98. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the firm earned $2.53 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 2.11% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Piper Sandler reaffirmed a "neutral" rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Barclays decreased their price target on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. Stifel Nicolaus cut their target price on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research report on Thursday, October 10th. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price target on the stock. Finally, Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $539.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.